Revolution Medicines publishes Nature studies on RMC-7977, a novel RAS(ON) tri-complex inhibitor, showing exceptional anti-tumor activity in preclinical PDAC models.
Revolution Medicines announces two Nature publications detailing RMC-7977, a new class of RAS(ON) multi-selective tri-complex inhibitor. The inhibitor exhibits unprecedented anti-tumor activity in preclinical RAS-mutant pancreatic ductal adenocarcinoma (PDAC) models, targeting both mutant and wild-type RAS forms. RMC-7977 drives potent and durable inhibition of RAS-mutated cancers at well-tolerated doses.
April 08, 2024
6 Articles